Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores

• Main Authors: Yan Huang (Author), Lichang Chen (Author), Rui Huang (Author), Chuanwu Zhu (Author), Jia Shang (Author), Yunsong Qian (Author), Jianqi Lian (Author), Longgen Liu (Author), Jianning Jiang (Author), Chenghai Liu (Author), Honglian Gui (Author), Qing Xie (Author)
• Format: Book
• Published: SAGE Publishing, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Both tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are known to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to compare the difference in HCC risk reduction between TDF and ETV in treatment-naïve patients with CH...